▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3989 by analyst upside · 2026-11-12
QGEN
Qiagen N.V.
Healthcare · Market Cap $10B · P/E 27.3x
ANALYST PRICE TARGET
-1.4%
implied upside to consensus target
Current Price $50.3
Consensus Target $49.59
Bull Target $53.0
Bear Target $40.0
Analysts Covering 11
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
0
Hold
10
Sell
0
52-Week Low $32.53
52-Week High $57.82
YTD Return +12.3%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 27.3x
Forward P/E 18.9x
EPS (TTM) $1.84
PEG Ratio 1.35
Dividend Yield 0.70%
Revenue (TTM) $2.1B
Profit Margin 18.2%
52-WEEK RANGE
52-Week Low $32.53
52-Week High $57.82
Current Price $50.3
Bear Target $40.0
Bull Target $53.0
● Now $50.3 ● Target $49.59
TRADING DATA
Avg Volume 3.8M
YTD Return +12.3%
Analyst Count 11
Consensus Hold
Upside to Target -1.4%
Last Updated 2026-11-12

ANALYST SUMMARY

Qiagen N.V. (QGEN) is currently trading at $50.3 with a Wall Street consensus price target of $49.59, which is 1.4% below the current price over the next 12 months. 11 analysts currently cover QGEN, with a consensus rating of Hold - 9% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $53.0, while the most cautious has a target of $40.0.

QGEN operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 12.3% year-to-date and is currently trading near the upper end of its 52-week range of $32.53 – $57.82.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QGEN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↓ Downgrade
Overweight → Equal-Weight 2026-10-28 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-10-26 Building track record
JP Morgan ↓ Downgrade
Overweight → Neutral 2026-10-22 43% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-10-22 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-10-14 43% win rate (7 calls)
Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-10-06 Building track record
UBS - Reiterated
Neutral → Neutral 2026-09-09 33% win rate (6 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-08-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
25/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →